Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
نویسندگان
چکیده
منابع مشابه
Minimal residual disease in multiple myeloma.
Multiple myeloma (MM) is a B-cell malignancy in which abnormal, clonal plasma cells proliferate and accumulate in the bone marrow. These abnormal cells, referred to as myeloma cells, disrupt normal bone marrow function and invade bone. Myeloma cells produce and secrete significant quantities of monoclonal protein (M-protein) into the blood and/or urine.1 The clinical features of MM include hype...
متن کاملState-of-the-art and future perspectives
Organic food products are highly susceptible to fraud. Currently, administrative controls are conducted to detect fraud, but having an analytical tool able to verify the organic identity of food would be very supportive. The state-of-the-art in food authentication relies on fingerprinting approaches that find characteristic analytical patterns to unequivocally identify authentic products. While...
متن کاملThalidomide in multiple myeloma: state of art.
Since the first report by Singhal et al. on the use of thalidomide in multiple myeloma (MM),1 an increasing bulk of evidence has confirmed the striking activity of this drug in the treatment of patients with advanced and refractory disease.2-6 The overall response rate in most studies so far reported averages approximately 30%. The mechanisms by which thalidomide exerts its action are as yet po...
متن کاملMembrane Science and Research in Asia and the Middle East: State of the Art and Perspectives
Asia and Middle East represent one of the most dynamic regions in the world which has experienced fast economic and technological growth. Access to clean and affordable water is essential for building resilience and maintaining human’s well-being and livelihood development in this region. Likewise, various energy resources are fundamental to support stable economic and social progress for bette...
متن کاملMinimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
With contemporary therapeutic strategies in multiple myeloma, heretofore unseen depth and rate of responses are being achieved. These strategies have paralleled improvements in outcome of multiple myeloma patients. The integration of the next generation of proteasome inhibitors and antibody therapeutics promise continued improvements in therapy with the expectation of consistent depth of respon...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Medicine
سال: 2020
ISSN: 2077-0383
DOI: 10.3390/jcm9072142